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Impact of endovascular options on lower
extremity revascularization in young patients
Cassius Iyad Ochoa Chaar, MD, Michel S. Makaroun, MD, Luke K. Marone, MD, Robert Y. Rhee, MD,
George Al-Khoury, MD, Jae S. Cho, MD, Steven A. Leers, MD, and Rabih A. Chaer, MD, Pittsburgh, Pa
Objective: This study assessed outcomes of revascularization strategies in young patients with premature arterial disease.
Methods: Lower extremity revascularization outcomes from 2000 to 2008 were retrospectively compared among
consecutive patients with comparable indications and procedures: age <50 years (group A) at the time of revasculariza-
tion, 51 to 60 years (group B), and >60 years (control group C). Patency, limb salvage, and survival by limb or patient
level were assessed by Kaplan-Meier and Cox proportional hazards analyses.
Results: A total of 409 limbs in 298 patients were treated: 44% for claudication and 56% for critical limb ischemia (CLI).
Group A patients weremore likely to be smokers and have a hypercoagulable state but less likely to have diabetes and renal
failure. Treatment indications were comparable among groups, and procedures were equally distributed between open
surgical and endovascular interventions. Two perioperative deaths occurred in group C (2%). Mean follow-up was 29
months, and 16% of claudicant patients in group A progressed to CLI (B, 3%; C, 2%; P < .001). Overall, 2-year primary,
primary assisted, and secondary patency were significantly lower in group A (50.5%, 65.2%, 68.2%; P .045) vs B (65.7%,
81.4%, 86.8%; P .01) and C (57.9%, 78.9%, 83.9%; P< .001). Claudicant patients in group A had an unexpectedly low
2-year freedom from major amputation after intervention of only 90%. Results were more comparable across groups for
CLI. The 2-year freedom from reintervention was similar (A, 81.0%; B, 78.9%; C, 83.5%), irrespective of the indication
for intervention (P  .60). Younger patients had a significantly higher 3-year survival (A, 89.5%; B, 85.3%) compared
with patients aged >60 years (C, 71.4%; P  .005). The 2-year freedom from major amputation rate was significantly
lower in claudicant patients in group A vs C undergoing endovascular revascularization (P  .002), but not in patients
treated with open revascularization (P  .40). Predictors of loss of primary patency included age <50 years (P  .003),
endovascular revascularization (P .005), and progression from claudication to CLI (P< .001). Age<50 years was also
an independent predictor of limb loss vs age >60 years (P  .05).
Conclusions: Endovascular options are commonly being used in young patients, especially those with claudication, but
patency rates and outcomes remain very poor. (J Vasc Surg 2012;56:703-13.)
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cPremature peripheral arterial disease (PAD) is a “viru-
lent” disease, as described by McCready et al1 in 1984.
Although the definition of premature PAD and the cutoff
age is controversial, the consensus among vascular surgeons
is that affected patients have a poor overall prognosis.2-4
Lower extremity revascularization (LER) in young patients
with bypass surgery can be safely and successfully per-
formed, but most studies show inferior patency and limb
salvage rates.5,6 In a recent study, Singh et al7 used the
National Surgical Quality Improvement Program (NSQIP)
database to demonstrate that patients aged 50 years and
those aged 51 to 60 years were significantly associated with
early infrainguinal arterial bypass graft failure compared
with patients aged 70 years.
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doi:10.1016/j.jvs.2012.01.073Despite the increasing use of endovascular procedures
or LER across age groups,8 there is a paucity of published
ata on the results of endovascular interventions in young
dults. This study was conducted to better characterize
remature PAD by comparing the outcomes of different
ge groups treated with LER and to assess the effect of
ndovascular interventions on LER in young patients
reated for a variety of indications.
ETHODS
This was a single-institutional retrospective review of a
rospectively maintained registry. The University of Pitts-
urgh Institutional Review Board approved the study pro-
ocol.
Patients. The medical records of patients who under-
ent LER for PAD related to atherosclerosis between 2000
nd 2008 were reviewed. Patients were considered to have
remature PAD if they underwent LER at age 60 years.
he cutoff age was defined based on the available litera-
ure.2,3,9,10 Recognizing the arbitrary definition of the
utoff age used, all patients with premature PAD were
ncluded and were further divided into two groups: group
(aged 50 years) and group B (aged 51-60 years). The
ontrol group included selected patients with compara-
le indications and types of interventions (open vs per-
utaneous) who underwent LER at age 60 (group C)
uring the same interval. Patient characteristics, includ-
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were noted. Chronic renal insufficiency was defined by
baseline serum creatinine 1.5 mg/dL, without the
need of dialysis. Morbid obesity was defined by a body
mass index 35 kg/m2.
Procedures. The indications for intervention were di-
vided into lifestyle-limiting claudication (Rutherford 3/4)
or critical limb ischemia (CLI) (Rutherford 5/6). The
decision to proceed with an open, an endovascular, or a
hybrid procedure was at the operating surgeon’s discretion.
All angiograms were reviewed to determine the level and
the severity of the disease according to the TransAtlantic
Inter-Society Consensus (TASC) II classification.11 Oper-
ative reports were reviewed for the level and type of bypass
(vein vs prosthetic) or the type and level of endovascular
intervention (angioplasty, stenting, atherectomy, cryo-
plasty, thrombolysis). Outcomes of 30-day morbidity and
death as well as the hospital length of stay and the propor-
tion of patients requiring intensive care unit stays were
recorded.
Follow-up. Noninvasive vascular laboratory surveil-
Table I. Patient characteristics divided by age groups
Patient characteristics a
Group A
(50 years)
(n  97)
Demographics
Age at surgery, years
Mean  SD 45  5
Median (range) 47 (30-50)
Male sex 57 (55)
White 90 (80)
Comorbidities
Diabetes 38 (37)
Type 1 17 (16)
Hypertension 76 (74)
Hypercholesterolemia 58 (56)
Coronary artery disease 43 (42)
Congestive heart failure 9 (9)
Prior CABG 10 (10)
COPD 11 (11)
Cirrhosis 1 (1)
End-stage renal disease 6 (6)
CRI 16 (16)
Stroke 6 (6)
Cancer 5 (5)
Morbid obesity 21 (17)
Hypercoagulable disorder 16 (15)
Social history
Smoking 82 (80)
Alcohol abuse 10 (10)
Medications
Aspirin 62 (60)
Warfarin 29 (28)
Insulin 29 (28)
Clopidogrel 43 (42)
Statin 44 (43)
-Blocker 47 (46)
CABG, Coronary artery bypass graft; COPD, chronic obstructive pulmonar
aContinuous data are shown as indicated, and categoric data as percentagelance was routinely performed on all patients at 1, 3, and 6 ronths after the procedure. Patients were then evaluated at
-month intervals. All patients were monitored clinically
or wound care, when applicable, to detect improvement in
ymptoms, recurrence of disease, and need for reinterven-
ion. In patients who were initially treated for claudication,
rogression to CLI in the same limb and reintervention for
imb salvage were specifically noted, along with the time to
onversion from claudication to CLI.
Outcomes. Each limb was analyzed separately in pa-
ients who required bilateral LER. Patency rates for open
ypasses were calculated according to the Rutherford cri-
eria.12 Primary patency was defined as uninterrupted pa-
ency, without the need of any open or endovascular inter-
ention on the vascular segment treated by the bypass.
ntervention on the artery beyond the graft and its two
nastomoses did not disqualify the bypass from primary
atency. Assisted primary patency applied to situations
here the bypass required prophylactic intervention before
oss of patency. Secondary patency referred to restoration
f bypass graft patency after occlusion. For endovascular
rocedures, primary patency was defined as the absence of
Group B Group C
P
(51-60 years) (60 years)
(n  103) (n  98)
56  3 73  8
56 (51-60) 73 (61-88)
65 (67) 63 (62) .44
85 (85) 90 (88) .47
43 (44) 62 (61) .002
10 (10) 2 (1) .008
81 (84) 87 (85) .17
64 (66) 69 (60) .28
55 (57) 62 (60) .03
23 (24) 26 (25) .007
25 (26) 35 (26) .001
24 (25) 23 (17) .05
3 (3) 1 (1) .6
19 (20) 13 (13) .02
23 (24) 33 (32) .03
18 (19) 22 (19) .007
12 (12) 16 (12) .06
11 (9) 17 (8) .23
5 (5) 3 (2) .004
79 (81) 62 (61) .003
10 (10) 8 (5) .85
69 (71) 73 (51) .3
11 (11) 11 (7) .001
30 (31) 38 (24) .44
56 (58) 46 (36) .16
57 (59) 63 (61) .02
57 (59) 73 (47) .005
se; CRI, chronic renal insufficiency.
er).y diseaestenosis or occlusion in the treated arterial segment and
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vention, surgical bypass, or progression of tissue loss re-
quiring amputation.
Patency was analyzed only for the first LER procedure
on each limb. Therefore, the limbs that underwent multiple
interventions for multilevel disease or for recurrent disease
had only one entry for patency corresponding to the first
LER procedure. Freedom from major amputation was de-
fined as the time from the first LER to the first major
below-knee or above-knee amputation.
Patients with premature PAD who underwent their first
LER at another institution and were transferred for subse-
quent complications were included only if the initial non-
invasive hemodynamic testing, angiograms, and operative
reports of their first procedure were available for review.
Survival was derived from the medical records and from the
Social Security Death Index.
Statistical analysis. Baseline demographic and clin-
Table II. Interventions and perioperative complications
Variables
Group A
(50 years)
(n  139)
Indication
CLI 53 (72)
Claudicant to CLI 16 (22)
Procedure
Percutaneous 40 (55)
Open surgery 56 (79)
Hybrid 4 (5)
TASC II distribution
Aortoiliac 46 (62)
Femoropopliteal 42 (56)
Tibioperoneal 13 (17)
Multilevel disease 14 (14)
TASC II score
A 7 (8)
B 14 (16)
C 21 (23)
D 58 (64)
Complications
Pseudoaneurysm 0 (0)
Bleeding 2 (2)
Wound infection 3 (4)
Pneumonia 5 (6)
UTI 2 (2)
Graft thrombosis 4 (5)
DVT/PE 5 (6)
MI 1 (1)
Acute renal failure 5 (6)
New dialysis 1 (1)
Return to OR 6 (8)
Morbidity 21 (20)
Mortality 0
Length of stay, days
Mean  SD 5  5
Median (range) 5 (0-28)
ICU admission 12 (15)
CLI, Critical limb ischemia; DVT, deep vein thrombosis; ICU, intensive car
pulmonary embolism; SD, standard deviation; TASC, TransAtlantic Inter-S
aContinuous data are shown as indicated, and categoric data as % (number)ical characteristics were first compared among the three 9ge groups by 2 test for categoric variables or the
ruskal-Wallis test for continuous variables. Trends by
ge were assessed using the Cochran-Mantel-Haenszel
est for categoric variables and the Jonckeheere-Terpstra
est for continuous and nominal/ordinal variables. Clin-
cal event rates, such as patency, freedom from major
mputation, and survival, were calculated by the Kaplan-
eier approach and compared by means of the log-rank
est for trend. Cox proportional hazards regression was
sed to estimate 2-year or 3-year risk ratios of clinical
vents in relation to age, with the time to event begin-
ing at the time of the procedure. Important covariates
or each multivariable model were identified from factors
hat differed significantly between the age groups and
ere also associated with the outcomes of interest using
tepwise Cox proportional hazards modeling methods.
he level of statistical significance was determined at a
alue of P  .05. All analyses were performed with SAS
Group B Group C
P
1-60 years) (60 years)
n  151) (n  119)
54 (82) 64 (76) .16
3 (5) 2 (2) .001
.15
51 (78) 51 (61)
46 (69) 48 (57)
3 (4) 1 (1)
.001
42 (63) 8 (9)
50 (76) 68 (80)
8 (12) 25 (29)
12 (12) 8 (8) .05
.03
11 (16) 18 (20)
24 (36) 19 (21)
17 (25) 24 (27)
48 (71) 39 (44)
2 (3) 2 (2) .28
1 (2) 1 (1) .93
11 (16) 5 (6) .03
1 (2) 1 (1) .11
0 (0) 2 (2) .25
2 (3) 3 (4) .27
0 (0) 0 (0) .003
1 (2) 1 (1) .91
1 (2) 3 (3) .24
0 (0) 1 (1) .54
7 (11) 5 (6) .14
21 (22) 17 (17) .05
0 2 (2) .21
5  7 4  7 .02
3 (0-30) 3 (0-40)
11 (16) 8 (9) .61
; LOS, length of stay; MI, myocardial infarction; OR, operating room; PE,
Consensus; UTI, urinary tract infection.(5
(
e unit.2 software (SAS Institute Inc, Cary, NC).
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Patients. The 298 patients in the study were divided
by age into three groups: 97 in group A (mean age, 45
years), 103 in group B (mean age, 56 years), and 98 in
group C (mean age, 73 years). Patient characteristics are
reported in Table I. Younger patients (group A) had a
lower incidence of coronary artery disease (CAD; P  .03)
and congestive heart failure (P .007) and had undergone
less coronary revascularization (P  .001). They also were
less likely to be diabetic (P .002), to have end-stage renal
disease (P  .02), or to have suffered a stroke (P  .007).
Even though the overall incidence of diabetes mellitus
(DM) was lower in group A, type 1 DM was significantly
more common in patients aged 50 years (P  .008).
Group A also had higher incidences of smoking (P .003)
and hypercoagulable disorders (P  .004). Younger pa-
tients were more likely to be taking warfarin (P .001) but
less likely to be taking a statin (P  .02) or -blocker (P 
.005).
Indications for intervention. A total of 409 limbs
were treated: 139 in group A, 151 in group B, and 119 in
group C (Table II). There was a preponderance of proce-
dures for CLI (Table II), but this was not different among
the three groups (A, 53%; B, 54%; C, 64%; P  .16).
Tibioperoneal disease was more prevalent in group C (25%)
than in groups A (13%) and B (8%), whereas aortoiliac
disease was more common in groups A (46%) and B (42%;
P  .001). Younger patients had more severe disease than
their elder counterparts, as reflected by a higher percent-
age of TASC D lesions: 58% in A vs 48% in B vs 39% in C
(P  .03). The proportion of patients with multilevel
disease was similar among the three groups (A, 14%; B,
12%; C, 8%).
Interventions. Open and percutaneous procedures
were equally used in the three groups and are summarized
in Table III. Prosthetic bypasses were mostly used for
Table III. Lower extremity revascularization procedures
in the three age groups
Procedure
Group A Group B Group C
(50 years) (51-60 years) (60 years)
Bypass
Prosthetic 27 24 6
Autogenous 23 25 37
Other opena 2 6 —
Hybridb 5 4 1
Angioplasty 3 10 17
Stenting 29 59 38
Atherectomyc 4 6 4
Lysis 5 . . . . . .
Cryoplasty 1 2 . . .
The numbers refer to procedures performed.
aIncluded endarterectomy, thrombectomy, and patch angioplasty.
bHybrid procedures were femoral endarterectomies with retrograde or
antegrade stenting.
cAtherectomy was performed with laser or Silverhawk (ev3, Plymouth,
Minn).aortoiliac disease and included aortobifemoral bypasses in C7, axillofemoral bypasses in four, and femorofemoral by-
asses in seven. Axillofemoral bypass was used as the initial
rocedure only in patients with hostile abdomen and med-
cal comorbidities that precluded aortobifemoral bypass
rafting. Only 14 infrainguinal bypasses were performed
sing prosthetic conduits. Bypasses to the popliteal artery
n  23) and to the tibial vessels (n  34) were predomi-
antly performed with autogenous conduit. Pedal bypasses
n  29) were exclusively autogenous. Hybrid procedures
n 10) included femoral endarterectomy with retrograde
liac or antegrade superficial femoral artery stenting. Most
atients treated percutaneously received angioplasty (n 
0) or stenting (n 126). Some patients were treated with
therectomy (n 14), cryoplasty (n  3), or thrombolysis
n  5). Thrombolysis was used to treat thrombosis in
oung patients with acute limb ischemia and hypercoagu-
able state. Adjunctive balloon angioplasty was used in
hree cases.
Patients in group A were more likely to progress from
laudication to CLI after intervention (P  .001). The
ean time to progression to CLI was 22 months. The 22
imbs in group A that progressed to CLI were initially
reated with open (n  15) and endovascular (n  7)
rocedures for claudication. The number and type of rein-
erventions to maintain limb perfusion in each patient were
abulated, averaging three reinterventions per patient. Six
imbs required major amputations, with four at the above-
nee level (Table IV).
Complications. Perioperative complications did not
iffer significantly among the three groups (A, 21%; B,
1%; C, 17%; Table II). The rate of postoperative infection
as higher in group B patients, and deep vein thrombosis
nd pulmonary emboli were more likely to develop in
roup A patients. Operative reinterventions were required
n 23 patients30 days of the index LER for thrombosis of
bypass graft or distal embolization in 11, for pseudoan-
urysm in 3, for wound debridement in 3, and for bleeding
n 1. Two patients required delayed leg fasciotomies for
ompartment syndrome, and two patients underwent a
racheostomy for respiratory failure. Two perioperative
eaths, from cardiac and respiratory failure, occurred in
roup C after bypass.
Hospital stay. The patients in group A had longer
ean stay (P  .02), and there was no difference in the
roportion of patients requiring intensive care unit admis-
ion among the three groups (Table II).
Patency. The mean follow-up was 29 months. The
-year primary patency (A, 50.5%; B, 65.7%; C, 57.9%; P
045; Fig 1), primary assisted patency (A, 65.2%; B, 81.4%;
, 78.9%; P .01; Supplementary Fig 1, online only), and
econdary patency (A, 68.2%; B, 86.8%; C, 83.9%; P 
001; Supplementary Fig 2, online only) were significantly
ower for group A than in groups B and C.
A similar trend was found when patients treated for
laudication were compared. There was a significantly
ower primary patency (A, 47.1%; B, 80.1%; C, 60.2%; P
006; Fig 2), primary assisted patency (A, 58.2%; B, 89.5%;
, 92.8%; P  .001; Supplementary Fig 3, online only),
i
b
e
on fe
r pati
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 3 Chaar et al 707and secondary patency (A, 62.7%; B, 94.0%; C, 92.8; P 
.001; Supplementary Fig 4) rates in claudicant patients
aged 50 years (group A). However, there was no signifi-
cant difference in patency rates among patients treated for
Table IV. List of reinterventions for claudicant patients in
ischemia (CLI)
Limb Initial intervention
O
1 CFA endarterectomy with patch angioplasty
2 Femoropopliteal bypass with prosthetic
3 Aortofemoral bypass
4 Aortofemoral bypass
5 Aortofemoral bypass
6 Superficial femoral artery stenting
7 Aortic stenting
8 Aortic stenting
9 Superficial femoral artery stenting
10 Femoropopliteal bypass with prosthetic
11 Aortofemoral bypass
12 Common iliac artery stenting
13 Common iliac artery stenting
14 Common iliac artery stenting
15 Femoropopliteal bypass with prosthetic
16 Femoropopliteal bypass with vein
17 Femoropopliteal bypass with prosthetic
18 Aortofemoral bypass
19 Aortofemoral bypass
20 Femoropopliteal bypass with prosthetic
21 Femoropopliteal bypass with prosthetic
22 Femorodistal bypass with vein
AKA, Above-knee amputation; BKA, below-knee amputation; CFA, comm
Fig 1. Kaplan-Meier curves show 2-year primary patency foCLI among the age groups (P  .4). pPatency was also assessed by open vs endovascular
ntervention among the three groups. There appeared to
e a consistent trend for lower patency rates overall for
ndovascular interventions in group A at 2 years com-
up A (age 50 years) who progressed to critical limb
einterventions
Progression to
CLI
(time in months) Amputation
Endovascular
(n)
1 15 . . .
0 1 . . .
0 44
0 15 AKA
0 15 . . .
2 8 . . .
1 7 . . .
1 7 AKA
2 7 BKA
0 11 . . .
0 38 . . .
5 32 . . .
0 8 . . .
0 8 . . .
1 12 AKA
2 6 . . .
1 6 AKA
0 85 . . .
0 85 . . .
2 23 . . .
0 9 . . .
3 15 BKA
moral artery.
ents in groups A (blue line), B (black line), and C (red line).gro
R
pen
(n)
1
4
4
2
3
0
2
4
6
1
1
1
0
0
1
5
2
1
1
3
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2ared with groups B and C. The primary patency of
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than for group B (53.4%) and group C (55.7%), but this
difference did not reach statistical significance (P  .19;
Fig 3). However, the difference was significant for pri-
Fig 2. Kaplan-Meier curves show 2-year primary patenc
line) treated for claudication.
Fig 3. Kaplan-Meier curves show 2-year primary patenc
line) treated with an endovascular procedure.mary assisted (A, 56.5%; B, 78.3%; C, 86.9%; P  .007; tupplementary Fig 5, online only) and secondary pa-
ency (A, 66.6%; B, 82.0%; C, 92.3%; P  .004; Supple-
entary Fig 6, online only) for endovascular procedures.
he patency of open procedures also showed a trend
atients in groups A (blue line), B (black line), and C (red
atients in groups A (blue line), B (black line), and C (redy for py for poward lower patency in group A at 2 years, but this was
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borderline for primary patency (P  .06) and primary
assisted patency (P  .15).
Freedom from major amputation. There was no
difference (P  .37) in the overall rates of freedom from
major amputation at 2 years among the three groups.
However, patients treated for claudication had a lower rate
of freedom from major amputation at 2 years in group A
(90.1%) than in groups B (92.3%; P  .36) and C (100%;
P  .05). The difference in freedom from major amputa-
tion among the three groups at 2 years was similar for
patients treated for CLI (P  .74). The 2-year freedom
from major amputation rate using endovascular LER was
inferior in group A (85.0%) compared with groups B
(89.7%) and C (100.0%; P  .01; Fig 4). No significant
difference was found in freedom from major amputation
rates at 2 years for patients in groups A, B, and C treated
with an open procedure (P  .40).
Reintervention. The overall rate of freedom from re-
intervention at 2 years was comparable among the three
groups (P  .60; Fig 5). There was no difference in
freedom from reintervention even when results were di-
vided by open (P .82) vs endovascular (P .22), or CLI
(P  .26) vs claudication (P  .43).
Survival. The overall 3-year survival was lower for
group C patients (71.4%) than for groups B (85.3%) and A
(89.5%; P  .005; Fig 6). This trend was reproducible
when comparing patients who were treated for CLI (P 
.002) and patients treated with an open procedure (P 
.001). There was no difference in 3-year survival between
patients in the three groups treated for claudication (P 
.97) or patients treated with an endovascular procedure
Fig 4. Kaplan-Meier curves show 2-year freedom from m
line), and C (red line) treated with an endovascular proc(P  .49). hMultivariable analysis. Cox proportional hazards
nalysis showed that older age at the time of intervention
group C vs group A) was protective against loss of primary
atency (hazard ratio [HR], 0.49; P  .003), loss of limb
HR, 0.36; P  .05), and reintervention (HR, 0.41; P 
04). Older age was also associated with increased long-
erm mortality (HR, 4.56; P .007). Compared with open
rocedures, endovascular procedures were associated with
significant loss of patency (HR, 1.77; P  .005) and a
igher rate of reintervention (HR, 2.45; P  .009) but
ere protective against long-term mortality (HR, 0.35;
 .01).
Aspirin use was protective against loss of patency (HR,
.68; P  .04) and reintervention (HR, 0.42; P  .007).
he univariate and multivariate models accounted for
ASC class and the use of warfarin anticoagulation, both of
hich did not reach statistical significance and did not
ffect the outcome measures among the three groups.
The progression of disease from claudication to CLI
as most predictive of loss of primary patency (HR, 3.34;
 .001). Renal disease was most predictive of long-
erm mortality (HR, 5.97; P  .001), regardless of age
Table V).
ISCUSSION
Premature PAD affects 2.1% of adults aged60 years.2
owever, there is no consensus regarding the cutoff age for
remature PAD. The division of patients (age 60 years)
nto two groups allowed better characterization of the
elationship of age and premature PAD. Patients aged50
ears had a significantly lower incidence of CAD, DM,
troke, and renal disease, although they were more likely to
amputation for patients in groups A (blue line), B (black
.ajorave type 1 DM, a hypercoagulable disorder, and to be
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September 2012710 Chaar et alsmokers. Even though CAD was a strong predictor of
premature PAD,2 with an incidence as high as 65% in one
study,3 the incidence of CAD in our population of young
adults with PAD was 43%. Our results are consistent with
other series reporting a lower incidence of CAD in patients
with premature PAD (29%-37%).5,9,13
Smoking was the most common risk factor in patients
Fig 5. Freedom from reintervention at 2 years is shown
line).
Fig 6. Survival at 3 years is shown for patients inaged 50 years in this series and has been uniformly peported as a risk factor for premature PAD, with a preva-
ence between 65%6 and 98%.3 Similar to our findings, Levy
t al9 also reported hypercoagulable disorders in 15% of
09 patients with PAD aged 40 years. However, the
ncidence of hypercoagulable disorders is likely underesti-
ated because a large number of the patients were not
ested. In two separate studies, serologic testing of young
atients in groups A (blue line), B (black line), and C (red
ps A (blue line), B (black line), and C (red line).for patients with premature PAD showed that approximately
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der.14,15
Most reports on the outcomes of LER in patients with
premature PAD focus on open interventions performed
during the past century,5,6,10,16 and very little has been
written on endovascular therapy.17 Here, we have de-
scribed the results of contemporary open and percutaneous
LER of a large group of patients with premature PAD from
a single institution compared with a selected group of older
controls. Despite recent trends in vascular surgery showing
a rapid rise in the number of endovascular interventions and
Table V. Regression models with significant factors
associated with loss of patency, loss of limb, reintervention,
and long-term mortality
Risk factors HR (95% CI) P
Associated with loss of
primary patency
Age (vs 50 years)
51-60 0.6 (0.388-0.913) .017
60 0.49 (0.309-0.791) .003
Aspirin use 0.68 (0.475-0.988) .04
Endovascular
procedure (vs
open) 1.77 (1.188-2.631) .005
Claudication to CLI 3.34 (1.856-6.014) .001
TASC distribution
(vs fempop)
Aortoiliac 0.44 (0.274-0.704) .001
Tibioperoneal 0.89 (0.534-1.487) .66
Associated with limb
loss
Age (vs 50 years)
51-60 0.65 (0.250-1.686) .37
60 0.36 (0.129-1.023) .05
TASC distribution
(vs fempop)
Aortoiliac 0.48 (0.126-1.801) .27
Tibioperoneal 3.22 (1.275-8.143) .01
Associated with
reintervention
Age (vs 50 years)
51-60 1.19 (0.587-2.402) .63
60 0.41 (0.179-0.958) .04
Aspirin use 0.42 (0.226-0.794) .007
Endovascular
procedure (vs
open) 2.45 (1.251-4.817) .009
Associated with long-
term mortality
Age (vs 50 years)
51-60 1.33 (0.388-4.587) .65
60 4.56 (1.508-13.803) .007
CABG 3.64 (1.750-7.572) .001
Chronic renal
insufficiency 5.97 (2.700-13.202) .001
Endovascular
procedure (vs
open) 0.35 (0.152-0.812) .01
CABG, Coronary artery bypass grafting; CI, confidence interval; CLI,
critical limb ischemia; HR, hazard ratio; TASC, TransAtlantic Inter-Society
Consensus.a decline in open bypass procedures,8 patients with prema- mure PAD in this study were equally distributed among
pen and endovascular procedures. In fact, a recent study
ased on New York state data showed that younger patients
aged 40-64 years) had the lowest increase in endovascular
nterventions for CLI and claudication compared with pa-
ients aged 65 to 79 years and octogenarians.18 Not sur-
rising, the patency of open and endovascular LER was
nferior in the youngest group.
Schillinger et al19 performed primary stenting in pa-
ients who were a mean age of 64 years and showed a
rimary patency of 54% at 2 years,19 consistent with our
ndings with endovascular therapy in groups B and C. In
ontrast, the primary patency of endovascular LER in
roup A was only 40%.
In a study examining endovascular therapy in patients
ith premature PAD, Levy et al17 reported a patency of
7% at 2 years. Percutaneous angioplasty was used to treat
2 patients (46 limbs) aged 45 years with aortoiliac
isease, mostly for claudication (84%).17 We noted lower
atency rates in our cohort, possibly because of a higher
roportion of patients with CLI (53%) and an increased
revalence of infrainguinal disease (54%).
The lower patency of LER in young adults did not
ranslate in this analysis into inferior overall clinical out-
omes with respect to freedom from major amputation and
eintervention. The freedom from major amputation was
nferior for patients aged50 years compared with the two
lder groups, but that difference did not reach statistical
ignificance. Harris et al13 reported the outcomes of open
ER in patients aged 50 years compared with a control
roup of patients aged60 years. There was an early trend
oward worsened limb salvage in patients with premature
AD that became significant only at 5 years of follow-up.
Also, the early results of the Bypass vs Angioplasty in
evere Ischemia of the Leg (BASIL) trial did not show a
ifference in amputation-free survival at 2 years.20 Subse-
uent results after 2 years showed a trend toward improved
mputation-free survival in patients treated with bypass
rst.21 Our follow-up period of 2 years may not have been
ong enough to show a significant difference in freedom
rom major amputation. However, subgroup analysis did
how that the youngest group of patients (aged50 years)
reated for claudication or treated with endovascular LER
ad inferior freedom from major amputation. In fact, pa-
ients treated for claudication in group A had a strikingly
igh rate (16%) of progression to CLI compared with only
% to 3% in the two groups of older patients.
Even though claudication is considered a relatively
enign condition in adults, leading to limb loss in 5%
fter 5 years of diagnosis,22 little is known about the natural
istory of claudication in young adults. In a small group of
1 patients aged45 years at the time of diagnosis, Valen-
ine et al3 monitored 22 patients with claudication for 73
onths. Of the patients treated with open LER for claudi-
ation, 44% required reintervention and progressed to CLI
20 months, whereas the medically treated patients re-
ained stable.3 These findings suggest that young adults
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sion to CLI, especially after LER.
Reintervention rates were similar among the three
groups. Despite lower primary patency, patients with clau-
dication may have enough symptomatic relief that can
explain the lower need for reintervention after restenosis.
Similarly, patients with tissue loss who heal and then de-
velop recurrence may not always require a reintervention.
Alternatively, patients who develop symptomatic recur-
rence and require reintervention may require multiple pro-
cedures. This applies particularly to claudicant patients with
premature PAD who progress to CLI after LER. The
patients in that group required an average of three reinter-
ventions, with one patient undergoing eight procedures
after superficial femoral artery stenting for claudication and
eventually requiring a below-knee amputation.
The mortality rate of patients with PAD in general and
premature PAD in particular remains high in this study and
consistent with the literature.4,21,23 Even though the sur-
vival of patients with premature PAD was higher than in the
older control group, they had a shorter life expectancy
compared with aged-matched individuals in the general
population. In our study, the mortality for patients with
PAD at a mean age of 45 (group A) was 10.5% at 3 years.
The mortality of a 45-year-old individual in the general
U.S. population, calculated over a period of 3 years, is 1.1%
as derived from the Social Security Period Life Table.24
Thus, premature PAD is associated with approximately a
10-fold increase in death. Others have reported similar
findings.4,21,23
Death was related to late cardiovascular events and is
therefore intricately influenced by medical management.
Most patients in this study were receiving antiplatelet ther-
apy with aspirin or clopidogrel. Despite the established role
of antiplatelet agents in the prevention of cardiovascular
events,25 our data failed to show a protective effect from
long-term death, probably because of the relatively small
sample size. Aspirin, however, was associated with im-
proved patency of LER and a decreased rate of reinterven-
tions. Statins were only prescribed to 44% of patients with
premature PAD, despite their documented survival bene-
fit.26,27 The reasons for this suboptimal medical manage-
ment are unclear but likely pertain to poor compliance or
tolerance, given that patients were adequately managed
otherwise.
The limitations of this study are inherent to its retro-
spective design. In addition, the data are based on a mixture
of open and endovascular interventions affecting different
anatomic levels of disease. Although the groups did not
differ statistically in the indications and types of procedures,
the TASC II distribution and severity of the lesions were
different. This difference, however, is expected given a
more common aortoiliac disease distribution in younger
patients and tibial disease in the elderly. Also, additional
stratification of each age group of patients based on ana-
tomic level of disease would have made the groups too
small to detect statistically significant differences. Also
noteworthy is that the comparison was made according tohe first intervention on each limb, which might have been
n oversimplification of the complex disease process affect-
ng those patients.
ONCLUSIONS
Premature PAD affects adults aged 50 years. Open
nd endovascular procedures seem to be equally used for
ER in patients with premature PAD but the outcomes are
nferior compared with older patients. In particular, endo-
ascular procedures have poor patency in young adults and
re associated with increased limb loss. Patients with pre-
ature PAD treated for claudication are also at risk of rapid
rogression to CLI, and when amputation is required, it
requently occurs at a more proximal level. Our current
ndings suggest that renewed caution in offering invasive
nterventions to patients with premature PAD is warranted
nless needed for limb salvage and that medical manage-
ent and risk factor modification should continue to be the
ainstay of therapy for patients with claudication. Con-
rolled prospective studies are needed to determine which
atients with premature PAD will benefit best from LER.
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